Myeloma biology and therapy. Present status and future developments.

[1]  B. Barlogie,et al.  Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. , 1997, Blood.

[2]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .

[3]  K. Takatsuki,et al.  Expression of Fas/Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders. , 1995, Blood.

[4]  S. Akira,et al.  Interleukin-6 family of cytokines and gp130. , 1995, Blood.

[5]  B. Klein,et al.  Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. , 1995, Blood.

[6]  J. Westendorf,et al.  Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines. , 1995, Blood.

[7]  J. Bourhis,et al.  Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma. , 1995, Stem cells.

[8]  B. Klein,et al.  Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. , 1995, Blood.

[9]  M. Tsuchiya,et al.  Establishment of a novel myeloma cell line KPMM2 carrying t(3;14)(q21;q32), which proliferates specifically in response to interleukin-6 through an autocrine mechanism. , 1995, Leukemia.

[10]  M. Boccadoro,et al.  High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. , 1995, Blood.

[11]  M. Laakso,et al.  Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. , 1995, Blood.

[12]  Y. Shima,et al.  Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. , 1995, Blood.

[13]  D. Siegel,et al.  Hypercalcaemia and increased serum interleukin‐6 levels induced by all‐trans retinoic acid in patients with multiple myeloma , 1995, British journal of haematology.

[14]  M. Dimopoulos,et al.  Early myeloablative therapy for multiple myeloma. , 1994, Blood.

[15]  H. Kung,et al.  Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains. , 1994, The Journal of clinical investigation.

[16]  B. Barlogie,et al.  Interleukin-6 prevents dexamethasone-induced myeloma cell death. , 1994, Blood.

[17]  Y. Shima,et al.  Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction [see comments] , 1994 .

[18]  Rasmus A. Rasmussen,et al.  Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma [see comments] , 1994 .

[19]  R. V. van Oers,et al.  Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. , 1994, Blood.

[20]  A. Waage,et al.  TNF and IL‐6 are potent growth factors for OH‐2, a novel human myeloma cell line , 1994, European journal of haematology.

[21]  M. Jourdan,et al.  Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. , 1994, Blood.

[22]  B. Klein,et al.  Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130 , 1994, The Journal of experimental medicine.

[23]  Y. Shima,et al.  Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130 , 1994, The Journal of experimental medicine.

[24]  M. Dimopoulos,et al.  The treatment of multiple myeloma. , 1994, The New England journal of medicine.

[25]  A. Tienhaara,et al.  Serum immunoreactive interleukin‐6 and C‐reactive protein levels in patients with multiple myeloma at diagnosis , 1994, British journal of haematology.

[26]  S. Akira,et al.  Cytokine signal transduction , 1994, Cell.

[27]  N. Udagawa,et al.  Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[28]  K. Anderson,et al.  Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. , 1993, Blood.

[29]  A. Freedman,et al.  Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. , 1993, Blood.

[30]  A. Morley,et al.  Advancement of multiple myeloma from diagnosis through plateau phase to progression does not involve a new B-cell clone: evidence from the Ig heavy chain gene. , 1993, Blood.

[31]  J. Woodliff,et al.  Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells , 1993 .

[32]  B. Klein,et al.  gamma-Interferon in multiple myeloma: inhibition of interleukin-6 (IL- 6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro , 1993 .

[33]  G. Gahrton,et al.  Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden , 1993 .

[34]  J. Saldanha,et al.  Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. , 1993, Cancer research.

[35]  C. Heirman,et al.  Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. , 1992, Blood.

[36]  L. Zon,et al.  Role of interleukin 6 in the growth of myelomaderived cell lines , 1992 .

[37]  B. Barlogie,et al.  Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. , 1992, Blood.

[38]  B. Barlogie,et al.  Primary dexamethasone treatment of multiple myeloma. , 1992, Blood.

[39]  I. Pastan,et al.  Interleukin-6 fused to a mutant form of Pseudomonas exotoxin kills malignant cells from patients with multiple myeloma. , 1992, Blood.

[40]  B. Mazières,et al.  Intensive combined therapy for previously untreated aggressive myeloma. , 1992, Blood.

[41]  E. Solary,et al.  Radioimmunoassay for the measurement of serum IL‐6 and its correlation with tumour cell mass parameters in multiple myeloma , 1992, American journal of hematology.

[42]  H. Sakamaki,et al.  Hypercalcaemia due to all-trans retinoic acid , 1992, The Lancet.

[43]  M. Jourdan,et al.  IFN-alpha induces autocrine production of IL-6 in myeloma cell lines. , 1991, Journal of immunology.

[44]  P. Sonneveld,et al.  In vitro Ig‐synthesis and proliferative activity in multiple myeloma are stimulated by different growth factors , 1991, British journal of haematology.

[45]  A. López-Guillermo,et al.  DEVELOPMENT OF AGGRESSIVE PLASMA CELL LEUKAEMIA UNDER INTERFERON‐ALPHA THERAPY , 1991, British journal of haematology.

[46]  M. Minden,et al.  Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the disease. , 1991, Blood.

[47]  M. Jourdan,et al.  Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. , 1991, Blood.

[48]  Y. Lévy,et al.  Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines. , 1991, The Journal of clinical investigation.

[49]  H. Imura,et al.  Establishment and characterization of four myeloma cell lines which are responsive to interleukin-6 for their growth. , 1991, Leukemia.

[50]  G. Gaidano,et al.  Role of bone marrow stromal cells in the growth of human multiple myeloma. , 1991 .

[51]  T. Hirano,et al.  Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors. , 1991, Journal of immunology.

[52]  M. Pettersson,et al.  Recombinant interferon‐ γ inhibits the growth of IL‐6‐dependent human multiple myeloma cell lines in vitro , 1991 .

[53]  T. Kishimoto,et al.  Heterogeneity in response to interleukin 6 (IL-6), expression of IL-6 and IL-6 receptor mRNA in a panel of established human multiple myeloma cell lines. , 1991, Leukemia.

[54]  T. Hamblin,et al.  Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. , 1991, Blood.

[55]  J. Ritz,et al.  Monoclonal Antibody-Purged Autologous Bone Marrow Transplantation Therapy for Multiple Myeloma , 1991 .

[56]  L. Neckers,et al.  Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. , 1991, Blood.

[57]  M. Jourdan,et al.  Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells [see comments] , 1990 .

[58]  T. Hirano,et al.  IL-6 is produced by osteoblasts and induces bone resorption. , 1990, Journal of immunology.

[59]  T. Suda,et al.  IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. , 1990, Journal of immunology.

[60]  F. Mandelli,et al.  Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. , 1990, The New England journal of medicine.

[61]  A. Carter,et al.  The role of interleukin‐1 and tumour necrosis factor‐α in human multiple myeloma , 1990 .

[62]  M. Jourdan,et al.  Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. , 1989, The Journal of clinical investigation.

[63]  L. Aarden,et al.  Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. , 1989, Biochemical and biophysical research communications.

[64]  F. D. Di Padova,et al.  Interleukin‐6 is produced by bone and modulated by parathyroid hormone , 1989, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[65]  G. Gaidano,et al.  Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma , 1989, The Journal of experimental medicine.

[66]  B. Klein,et al.  Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. , 1989, Blood.

[67]  P. Lansdorp,et al.  Production of interleukin-1 by bone marrow myeloma cells , 1989 .

[68]  H. Asaoku,et al.  Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma. , 1989, Blood.

[69]  C. Morimoto,et al.  Response patterns of purified myeloma cells to hematopoietic growth factors. , 1989, Blood.

[70]  H. Asaoku,et al.  Interleukin-1 beta rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma. , 1989, Blood.

[71]  B. Barlogie,et al.  Plasma cell myeloma--new biological insights and advances in therapy. , 1989, Blood.

[72]  M. Jourdan,et al.  Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. , 1989, Blood.

[73]  S. Shimizu,et al.  Establishment of two interleukin 6 (B cell stimulatory factor 2/interferon beta 2)-dependent human bone marrow-derived myeloma cell lines , 1989, The Journal of experimental medicine.

[74]  H. Asaoku,et al.  Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas , 1988, Nature.

[75]  T. Bringman,et al.  Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. , 1987, The New England journal of medicine.

[76]  T. Taniguchi,et al.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin , 1986, Nature.

[77]  B. Barlogie,et al.  Treatment of multiple myeloma with recombinant alpha-interferon. , 1986, Blood.

[78]  B. Johansson,et al.  Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden. , 1984, Cancer treatment reports.

[79]  S. Salmon,et al.  Effects of cloned human leukocyte interferons in the human tumor stem cell assay. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  H. Strander,et al.  INTERFERON THERAPY IN MYELOMATOSIS , 1979, The Lancet.

[81]  G. Mundy,et al.  Evidence for the secretion of an osteoclast stimulating factor in myeloma. , 1974, The New England journal of medicine.

[82]  E. A. Edwards.  Nonarterial Disorders Simulating Disease of the Peripheral Arteries , 1941 .

[83]  C. Schiffer,et al.  A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  S. Akira,et al.  Interleukin-6 in biology and medicine. , 1993, Advances in immunology.

[85]  K. Takatsuki,et al.  Autocrine growth by two cytokines, interleukin-6 and tumor necrosis factor alpha, in the myeloma cell line KHM-1A. , 1990, Acta haematologica.